To determine whether the TP53 and ATM comutation had a significant association with an increased TMB, we compared the mutation load of samples among patients who had the comutation, the TP53 mutation alone, the ATM mutation alone, or no mutation in 5 independent NSCLC cohorts: TCGA,15 MSKCC 341 NGS panel genes, MSKCC 410 NGS panel genes,19 Geneplus, and POPLAR4 and OAK.20 All comparisons indicated that the TP53 and ATM comutation was associated with a significantly higher TMB compared with the other 3 groups in all cohorts. The gene discussed is ATM; the disease is non-small cell lung carcinoma.